| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3999570 | Urologic Oncology: Seminars and Original Investigations | 2016 | 7 Pages |
Abstract
These real-world data on post-docetaxel AA efficacy are in line with the COU-AA-301 trial. Importantly, incidence of severe anemia and hypokalemia is up to 50% higher than reported in previous studies.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Charles M.D., Sylvie M.D., Ph.D., Fransien M.D., Gino M.D., Wim M.D., Filip M.D., Wim M.D., Thierry M.D., Peter M.D., Bertrand M.D., Dennis M.D., Ph.D., Jean-Pascal M.D., Ph.D., Dirk M.D., Els M.D., Lionel M.D., Patrick M.D., Joanna M.D., Jeroen M.D.,